<DOC>
	<DOCNO>NCT01256775</DOCNO>
	<brief_summary>Peripheral arterial disease ( PAD ) almost invariably associate generalize atherosclerotic involvement arterial tree endothelial dysfunction . Previous short term study show improvement vascular reactivity walk capacity PAD patient measure aim restore Nitric Oxide ( NO ) production . NO also know prevent progression atherosclerosis . We wish assess whether prolonged administration NO-donating agent ( NCX 4016 ) improve functional capacity PAD patient affect progression atherosclerosis assess carotid intima-media thickness ( IMT ) . Four hundred forty two patient stable intermittent claudication enrol prospective , double blind , placebo-controlled study randomize either NCX 4016 800mg bid placebo 6 month . The primary study outcome absolute claudication distance ( ACD ) constant treadmill test ( 10 % incline , 3km/hr ) ; main secondary end-point change mean far-wall right common carotid artery IMT .</brief_summary>
	<brief_title>Effect NCX4016 Walking Distance Patients With Peripheral Arterial Occlusive Disease ( PAOD )</brief_title>
	<detailed_description>Design study This prospective , randomize , double-blind , parallel-groups , placebo-controlled study conduct fortythree clinical site throughout Europe . 442 patient peripheral arterial occlusive disease ( PAD ) Leriche-Fontaine stage II treat NCX 4016 800 mg bid indistinguishable placebo 6 month . The dosage 800 mg bid select base previous clinical study , demonstrate good safety profile good tolerability gastro intestinal tract . Compliance check count dispense versus return study medication . All patient receive 100 mg aspirin daily cardiovascular prevention , standard patient population time study design . Inclusion criterion : male female patient 40 80 year Leriche-Fontaine stage II PAD present symptom intermittent claudication stable least 6 month , ankle/brachial index &lt; 0.9 , absolute claudication distance ( ACD ) &lt; 500 initial claudication distance ( ICD ) &gt; 50 standardize treadmill test ( 3 % incline , 3 km/hr ) , clinical stability inclusion ( i.e . change ACD exceed 25 % two standardized treadmill test run-in ) . All patient give write informed consent . Exclusion criterion : unstable symptom and/or rapid deterioration PAD previous 3 month ; presence clinically significant renal hepatic failure , insulin-dependent type 1 diabetes ; uncontrolled type 2 diabetes , arterial hypertension dyslipidemia ; clinical condition limit patient 's exercise ability ( angina pectoris , congestive heart failure , respiratory disease , bone joint disease , neurological disorder ) ; active peptic ulcer previous 6 month ; hemorrhagic condition history bleeding ; acute coronary syndrome acute cerebrovascular episodes previous 6 month ; previous revascularization procedure last 6 month indication vascular surgery ; ischemic rest pain ; life expectancy &lt; 12 month ; pregnancy lactation ; participation investigational trial within 3 month prior inclusion ; history hypersensitivity form allergic reaction contraindication NSAIDs , aspirin , NO-donating drug . The following treatment allow period study : continuative use ( &gt; 7 day ) NSAIDs nitrovasodilating drug ; phosphodiesterase type 5 inhibitor , anticoagulant , heparin , ticlopidine , clopidogrel , indobufen , defibrotide , mesoglycan , picotamide , pentoxyfylline , carnitine , sulodexide . All concomitant treatment keep constant much possible study period . Primary end-point study ACD constant treadmill test ; secondary end-points ICD ; responder rate , i.e . proportion patient show &gt; =28 % &gt; =50 % improvement ACD comparison baseline ; quality life questionnaire Short-Form 36 ( SF-36 ) ; variation ankle/brachial index ( ABI ) baseline 6 month modification intimal medial thickness ( IMT ) common right carotid artery 6 month compare baseline . Common right carotid artery examine B-mode ultrasound longitudinal view , 1-1.5 cm proximally bifurcation . The measurement IMT obtain accord Mannheim carotid intima-media thickness consensus one modification : instead acquire vascular wall image lateral probe incidence , image acquire also anterior posterior incidence , order obtain triplicate number measurement use comparison . Each position visualize record least 15 sec . simultaneous take ECG tracing . Images far wall distal 1 cm right common carotid artery obtain . IMT calculate three projection final value calculate average measurement use standardized ultrasonography setting . The baseline carotid ultrasonographic examination use localize site interest follow-up . Digitized still image electrocardiographically define diastolic frame analyzed offline . A single observer unaware treatment assignment identities patient measure mean carotid intima medium thickness . Focal atherosclerotic plaque exclude measurement . All measurement perform use automated border detection system . A number measurement inferior 30 three image acquisition incidence carry 1cm segment carotid artery assess . For subject ultrasound system transducer operator use throughout study . Images centrally analyze coordinate center dedicate , automate computerized edge detection system measurement common carotid far wall intima-media use software M'ATH 2.0 ( Metris Argenteuil , France ) .</detailed_description>
	<mesh_term>Intermittent Claudication</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Nitroaspirin</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>male female patient 40 80 year LericheFontaine stage II PAD present symptom intermittent claudication stable least 6 month ankle/brachial index &lt; 0.9 absolute claudication distance ( ACD ) &lt; 500 initial claudication distance ( ICD ) &gt; 50 standardize treadmill test ( 3 % incline , 3 km/hr ) clinical stability inclusion ( i.e . change ACD exceed 25 % two standardized treadmill test runin ) . patient give write informed consent . unstable symptom and/or rapid deterioration PAD previous 3 month presence clinically significant renal hepatic failure , insulindependent type 1 diabetes uncontrolled type 2 diabetes , arterial hypertension dyslipidemia clinical condition limit patient 's exercise ability ( angina pectoris , congestive heart failure , respiratory disease , bone joint disease , neurological disorder ) active peptic ulcer previous 6 month hemorrhagic condition history bleed acute coronary syndrome acute cerebrovascular episodes previous 6 month previous revascularization procedure last 6 month indication vascular surgery ; ischemic rest pain life expectancy &lt; 12 month pregnancy lactation participation investigational trial within 3 month prior inclusion history hypersensitivity form allergic reaction contraindication NSAIDs , aspirin , NOdonating drug follow treatment allow period study : continuative use ( &gt; 7 day ) NSAIDs nitrovasodilating drug phosphodiesterase type 5 inhibitor , anticoagulant , heparin , ticlopidine , clopidogrel , indobufen , defibrotide , mesoglycan , picotamide , pentoxyfylline , carnitine , sulodexide All concomitant treatment keep constant much possible study period .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>atherosclerosis</keyword>
	<keyword>carotid intima-media thickness</keyword>
	<keyword>intermittent claudication</keyword>
	<keyword>Nitric Oxide / NO</keyword>
</DOC>